Last updated: 2026-10-13 19:17:20. Prices reflect the latest regular market data. Stock price data is sourced from Massive.
Evolus, Inc. (EOLS) operates in the PHARMACEUTICAL PREPARATIONS sector and is listed on NASDAQ. The stock is currently priced at $7.51, with a market capitalisation of $510.57M and a P/E ratio of --. Over the past 52 weeks, its price has ranged from $3.86 to $9.31. This page covers its latest market performance, valuation, price trends and company information.
$510.57M | |
$7.68 | |
$39.50 | |
$2.85 | |
$7.75 | |
390.47K | |
897.86K | |
-- | |
$9.31 | |
$3.86 | |
-- | |
-- |
Evolus, Inc. (EOLS) is currently trading at $7.51 as of 2026-10-13 19:00:02, down 3.08% ($0.24) from the previous close of $7.75
During today's regular trading session, EOLS has traded between $2.85 and $39.50, with a trading volume of 390.47K shares. The current price is near the lower end of today's range.
Over the past seven days, Evolus, Inc. (EOLS) moved from $7.14 to $7.51, representing a gain of 5.20% ($0.37).
The stock traded between $6.91 and $7.83 during the period. The latest price is near the middle of the 7-day range, indicating strong upward.
The average daily volume was 946.68 thousand shares, up versus the previous seven-day period, indicating higher trading activity.
Position in Range: 67.0%
EOLS is currently trading at $7.51, placing it 67.0% of the way from its 52-week low of $3.86 to its 52-week high of $9.31. This percentage reflects the stock's relative position within its 52-week trading range, not its valuation or future performance.
Evolus Inc is a performance beauty company offering medical aesthetic products in the cash-pay aesthetic market. The company's commercially available products represent two product categories within medical aesthetics: injectable neurotoxins and injectable hyaluronic acid (HA) gels. Its commercial products are: Jeuveau, a proprietary 900-kilodalton, purified botulinum toxin type A formulation indicated for the temporary improvement in the appearance of moderate to severe frown lines, in adults; and Evolysse, a collection of injectable HA gels that utilizes first-generation cold technology. The line includes several products, including mid face, nasolabial folds, lips, and eyes. Geographically, the company currently has operations in the United States, Canada, Europe, and Australia.
| Industry | PHARMACEUTICAL PREPARATIONS |
| Employees | 353 |
| Exchange | NASDAQ |
| Company Website |
Eligible investors can buy real shares of Evolus, Inc. (EOLS) through MEXC RealStocks. Follow these three steps to open a RealStocks account, transfer USDT, and place a US stock order.